Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by up to 55 percent. This change begins on April 3, 2026. The aim is to help more people manage obesity. This move supports Emcure's commitment to better health outcomes.